Progesterone Clinical Trial
Official title:
The Efficacy of Progestins in Treatment of Functional Ovarian Cyst
The aim of this study is to determine whether the use of progesterone only pills has a beneficial effect over the expectant management of functional ovarian cyst or not , through a sample of female patients within the reproductive years
Status | Not yet recruiting |
Enrollment | 90 |
Est. completion date | September 1, 2020 |
Est. primary completion date | May 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 44 Years |
Eligibility |
Inclusion Criteria: - Female patients at reproductive age (18-44) Menstruating ovarian cyst (a cyst 3-10 cm in diameter, unilateral , unilocular ,clear content) BMI : patients with normal BMI (18.5-24.9) and overweight (25-29.9) included Exclusion Criteria: - Exclusion criteria are ovarian payhology (dermoid, endometriosis or malignancies) Complicated cyst (rupture, torsion) Patients receiving hormonal treatment for the previous 3 cycles History of surgical removal of ovarian cyst Comorbidities like uncontrolled DM ,hypertension and tuberculosis |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Goh W, Bohrer J, Zalud I. Management of the adnexal mass in pregnancy. Curr Opin Obstet Gynecol. 2014 Apr;26(2):49-53. doi: 10.1097/GCO.0000000000000048. Review. — View Citation
Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev. 2014 Apr 29;(4):CD006134. doi: 10.1002/14651858.CD006134.pub5. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | disappearance of cyst | ultrasound evaluation Post-menstrual or delayed menses for 1 week after treatment Patients will be asked about residual symptoms Then TVUS if resolved , another examination will be scheduled after 1 month post-menstrual decreasing in size , another course of treatment will be offered stationary or increasing ,patient will be offered COCs (0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) complicated ( torsion or rupture ) , patient will be subjected to surgery |
2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03340701 -
Pharmacokinetics of Progesterone in Pregnancy
|
Phase 1 | |
Completed |
NCT04535973 -
Hormonal Status and Quality of Life in Female Postmenopausal Patients With Burning Mouth Syndrome
|
||
Completed |
NCT03740568 -
Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes.
|
N/A | |
Terminated |
NCT04140968 -
Progesterone and Resting Energy Expenditure
|
Phase 4 | |
Completed |
NCT03677336 -
Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI
|
Phase 4 | |
Completed |
NCT05742503 -
Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level
|
||
Completed |
NCT02323347 -
Cut-Off Progesterone Values Deleterious for In Vitro Fertilization and Fresh Embryo Transfer
|
N/A | |
Completed |
NCT00264407 -
Neural Changes in the Aging Auditory System
|
Phase 1 | |
Recruiting |
NCT04124913 -
Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles
|
Phase 4 | |
Completed |
NCT03734770 -
Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support
|
N/A | |
Completed |
NCT04253470 -
Debate on Progesterone Elevation on the Day of Triggering
|
||
Completed |
NCT04769401 -
Effects of E2, P4 and LH Levels on the Day of Transfer and Endometrial Cavity Thickness on Implantation Success in Patients With Frozen-thawed Embryo Transfer Cycle
|
N/A | |
Recruiting |
NCT05481684 -
The Importance of Embryo Transfer Day Progesterone Value in Natural Cycle Frozen Embryo Transfers and the Evaluation of the Effect of Rescue Therapy on Pregnancy Outcomes in Patients With Low Progesterone Levels
|
N/A | |
Completed |
NCT05276531 -
Comparison of the Effect of Subcutaneous Progesterone and Vaginal Progesterone for Luteal Phase Support
|
N/A |